In yesterday’s Wall Street session, GoodRx Holdings Inc. (NASDAQ:GDRX) shares traded at $8.67, down -6.17% from the previous session.
As of this writing, 21 analysts cover GoodRx Holdings Inc. (NASDAQ:GDRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $12.00 and a low of $5.00, we find $6.63. Given the previous closing price of $9.24, this indicates a potential downside of -28.25 percent. GDRX stock price is now 46.06% away from the 50-day moving average and 59.44% away from the 200-day moving average. The market capitalization of the company currently stands at $3.38B.
There are 15 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $6.79 as their price target over the next twelve months.
With the price target enhanced from $6.50 to $12, TD Cowen Upgraded its rating from Market Perform to Outperform for GoodRx Holdings Inc. (NASDAQ: GDRX).
Insiders disposed of 262,673 shares of company stock worth roughly $2.28 million over the past 1 year. A total of 1.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GDRX stock. A new stake in GoodRx Holdings Inc. shares was purchased by INTEGRAL HEALTH ASSET MANAGEMENT, LLC during the first quarter worth $1,760,000. QUANTBOT TECHNOLOGIES LP invested $912,000 in shares of GDRX during the first quarter. In the first quarter, NEW YORK LIFE INVESTMENT MANAGEMENT LLC acquired a new stake in GoodRx Holdings Inc. valued at approximately $680,000. STONNINGTON GROUP, LLC acquired a new stake in GDRX for approximately $264,000. VIRTU FINANCIAL LLC purchased a new stake in GDRX valued at around $198,000 in the second quarter. In total, there are 211 active investors with 69.50% ownership of the company’s stock.
Tuesday morning saw GoodRx Holdings Inc. (NASDAQ: GDRX) opened at $9.22. During the past 12 months, GoodRx Holdings Inc. has had a low of $3.82 and a high of $10.37. As of last week, the company has a debt-to-equity ratio of 0.79, a current ratio of 13.10, and a quick ratio of 13.10. The fifty day moving average price for GDRX is $6.01 and a two-hundred day moving average price translates $5.46 for the stock.
The latest earnings results from GoodRx Holdings Inc. (NASDAQ: GDRX) was released for Mar, 2023. According to the Health Information Services Company, earnings per share came in at $0.07, beating analysts’ expectations of $0.06 by 0.01. This compares to $0.03 EPS in the same period last year. The net profit margin was -6.50% and return on equity was -6.00% for GDRX. The company reported revenue of $183.99 million for the quarter, compared to $203.33 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -9.51 percent. For the current quarter, analysts expect GDRX to generate $186.82M in revenue.
GoodRx Holdings Inc.(GDRX) Company Profile
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is headquartered in Santa Monica, California.
